C55-isoprenyl pyrophosphate · SMALL MOLECULE · Bacteria
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14C55-isoprenyl pyrophosphate shows approved-linked disease relevance led by bacterial disease. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Use bacterial disease as the disease frame, then confirm a stable protein accession before cross-source reuse.
Use bacterial disease as the disease frame, then confirm a stable protein accession before cross-source reuse.
C55-isoprenyl pyrophosphate shows approved-linked disease relevance led by bacterial disease. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with bacterial disease because it currently carries approved-linked support. Linked drugs include BACITRACIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyC55-isoprenyl pyrophosphate
Review this target as C55-isoprenyl pyrophosphate.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats C55-isoprenyl pyrophosphate as ChEMBL target CHEMBL2364036. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether C55-isoprenyl pyrophosphate still has a stable protein naming contract across sources.
Jump to Protein ContextUse this block first when you need to confirm why bacterial disease is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | C55-isoprenyl pyrophosphate |
| Target Type | SMALL MOLECULE |
| Organism | Bacteria |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | C55-isoprenyl pyrophosphate |
| UniProt Accession | N/A |
C55-isoprenyl pyrophosphate
Review this target as C55-isoprenyl pyrophosphate.
Open Targets-ready disease context using the current target-indication evidence contract.
C55-isoprenyl pyrophosphate shows approved-linked disease relevance led by bacterial disease. 5 more disease programs remain visible in the same review block.
Start review with bacterial disease because it currently carries approved-linked support. Linked drugs include BACITRACIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.